Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA(R) (isavuconazole) open-label study for ...
BASEL, Switzerland, March 9, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that results from the open-label phase 3 VITAL study evaluating CRESEMBA® (isavuconazole) in adult patients with mucormycosis were published in The …